Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAVXR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS 3	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAplus.
NEWS 4	OCT 21	CA/CAplus kind code changes for Chinese patents increase consistency, save time
NEWS 5	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS 6	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS 7	NOV 03	New format for Korean patent application numbers in CA/CAplus increases consistency, saves time.
NEWS 8	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS 9	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS 10	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS 11	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS 12	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS 13	DEC 18	ReaxysFile available on STN
NEWS 14	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS 15	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAplus
NEWS 16	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS 17	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS 18	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS 19	JAN 28	CABA will be updated weekly
NEWS 20	FEB 23	PCTFULL file on STN completely reloaded
NEWS 21	FEB 23	STN AnaVist Test Projects Now Available for Qualified Customers
NEWS 22	FEB 25	LPCI will be replaced by LDPCI
NEWS 23	MAR 07	Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN

NEWS EXPRESS 17 DECEMBER 2010 CURRENT WINDOWS VERSION IS V8.4.2 .1,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2011.

```
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.23       0.23

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 APR 2011  HIGHEST RN 1278651-19-6
DICTIONARY FILE UPDATES:  11 APR 2011  HIGHEST RN 1278651-19-6

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\vrodriguezgarcia\My Documents\e-Red
Folder\10598846\L1.str
```



chain nodes :
22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24
25 26 27 28
chain bonds :
11-16 19-22 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-28 24-25 25-26
26-27 27-28
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 16-17 16-21 17-18 18-19 19-20 19-22 20-21
exact bonds :
11-16 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15 23-24 23-28
24-25 25-26 26-27 27-28

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

L1 STRUCTURE UPLOADED

```
=> s sam sss l1
SAMPLE SEARCH INITIATED 08:45:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      284 TO ITERATE

100.0% PROCESSED      284 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4669 TO     6691
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> file zcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.04       2.27

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 13 Apr 2011  VOL 154 ISS 16
FILE LAST UPDATED: 12 Apr 2011  (20110412/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2011

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s sam sss l1
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




SAMPLE SEARCH INITIATED 08:46:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      284 TO ITERATE
```

```
100.0% PROCESSED      284 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4669 TO     6691
PROJECTED ANSWERS:               1 TO       80

L3            1 SEA SSS SAM L1



L4           0 L3

=> file registry
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.08       2.94

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 APR 2011  HIGHEST RN 1278651-19-6
DICTIONARY FILE UPDATES:  11 APR 2011  HIGHEST RN 1278651-19-6

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s sam sss l1
SAMPLE SEARCH INITIATED 08:46:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      284 TO ITERATE

100.0% PROCESSED      284 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4669 TO     6691
PROJECTED ANSWERS:               1 TO       80

L5            1 SEA SSS SAM L1

=> d sca
```

L5 1 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
    8-chloro-6,11-dihydro-11-[1-[1-(3-pyridinyl)ethyl]-4-piperidinylidene]-
MF C26 H26 Cl N3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Documents and Settings\vrodriguezgarcia\My Documents\e-Red Folder\10598846\L6.str



chain nodes :
22 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24 25 26 27 28
chain bonds :
11-16 19-22 22-23 22-29 22-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13 13-14 14-15 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 16-17 16-21 17-18 18-19 19-20 19-22 20-21
exact bonds :
11-16 22-23 22-29 22-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15 23-24 23-28 24-25 25-26 26-27 27-28

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS 30:CLASS

```
L6      STRUCTURE UPLOADED

=> s sam sss l6
SAMPLE SEARCH INITIATED 08:48:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      284 TO ITERATE

100.0% PROCESSED      284 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4669 TO     6691
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=> s full sss l6
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 08:50:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     5877 TO ITERATE

100.0% PROCESSED     5877 ITERATIONS                              31 ANSWERS
SEARCH TIME: 00.00.01

L8           31 SEA SSS FUL L6

=> file zcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 200.43     203.37

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 13 Apr 2011  VOL 154 ISS 16
FILE LAST UPDATED: 12 Apr 2011  (20110412/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2011

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
```

```
=> s l8
L9          124 L8

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                             ENTRY    SESSION
FULL ESTIMATED COST                                           1.84     205.21

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 APR 2011  HIGHEST RN 1279198-64-9
DICTIONARY FILE UPDATES:  12 APR 2011  HIGHEST RN 1279198-64-9

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d sca l8

L8   31 ANSWERS   REGISTRY  COPYRIGHT 2011 ACS on STN
IN   3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-
     benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]-
MF   C26 H24 Cl N3 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, nitrate (1:?)
MF C26 H26 Cl N3 . x H N O3

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
MF C26 H26 Cl N3 . x C4 H6 O6

CM 1



CM 2

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(1-oxido-3-pyridinyl)methyl]-4-piperidinylidene]-
MF C25 H24 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
    8-chloro-6,11-dihydro-11-[1-[(6-methyl-3-pyridinyl)methyl]-4-
    piperidinylidene]-, hydrochloride (1:3)
MF C26 H26 Cl N3 . 3 Cl H



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-
    benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]-,
    methyl ester
MF C27 H26 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, sulfate (1:?)
MF C26 H26 Cl N3 . x H2 O4 S

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
11-[1-[(5-bromo-3-pyridinyl)methyl]-4-piperidinylidene]-8-chloro-6,11-dihydro-
MF C25 H23 Br Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(2-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-
MF C26 H26 Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file zcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.02	206.23

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Apr 2011 VOL 154 ISS 16
FILE LAST UPDATED: 12 Apr 2011 (20110412/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

```
     (FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

     FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
L1             STRUCTURE UPLOADED
L2           1 S SAM SSS L1

     FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
               S L1

     FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
L3           1 S L1 SSS SAM

     FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
L4           0 S L3 SSS SAM

     FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
L5           1 S SAM SSS L1
L6             STRUCTURE UPLOADED
L7           0 S SAM SSS L6
L8          31 S FULL SSS L6

     FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
L9         124 S L8

     FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

     FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011

=> s l9 and (crystal or crystalline)
       1632422 CRYSTAL
        765969 CRYSTALS
       1962260 CRYSTAL
                  (CRYSTAL OR CRYSTALS)
         98110 CRYSTALLINE
           343 CRYSTALLINES
         98423 CRYSTALLINE
                  (CRYSTALLINE OR CRYSTALLINES)
        419323 CRYST
          1805 CRYSTS
        420595 CRYST
                  (CRYST OR CRYSTS)
        454916 CRYSTALLINE
                  (CRYSTALLINE OR CRYST)
L10          4 L9 AND (CRYSTAL OR CRYSTALLINE)

=> d ibib abs hitstr 1-4
THE ESTIMATED COST FOR THIS REQUEST IS 23.84 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L10  ANSWER 1 OF 4  ZCAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:        2008:1521725  ZCAPLUS
DOCUMENT NUMBER:         150:84138
TITLE:                   Quality control method of rupatadine fumarate
INVENTOR(S):             Peng, Hongwei; Yang, Wei; Zhao, Bin; Zeng, Yujian;
                         Zhao, Haifeng; Dong, Zhaoyong
PATENT ASSIGNEE(S):      Guangdong Kanghong Pharmaceutical Co. , Ltd., Peop.
                         Rep. China
SOURCE:                  Faming Zhuanli Shenqing Gongkai Shuomingshu, 39pp.
                         CODEN: CNXXEV
DOCUMENT TYPE:           Patent
LANGUAGE:                Chinese
```

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101324551	A	20081217	CN 2007-10028542	20070612

PRIORITY APPLN. INFO.: CN 2007-10028542 20070612

AB Rupatadine fumarate is a kind of anti-allergic medicine with antihistamine effect and antagonistic activity to platelet activating factor, and can be used for treating allergic rhinitis. The title quality control method of rupatadine fumarate comprises of: (1) part of or whole character inspection of appearance, hygroscopicity, solubility and m.p., (2) functional group identification via high performance liquid chromatog. and/or IR spectroscopic anal., (3) part of or whole detection of chlorides, relative substances, organic residues, loss on drying, combustion residue, and heavy metals, and (4) rupatadine fumarate content measurement via high performance chromatog. and/or nonaq. titration The quality control method has high specificity, stability and accuracy, and is simple in operation.

IT 158876-82-5, Rupatadine
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(quality control method of rupatadine fumarate)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L10 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:927512 ZCAPLUS
DOCUMENT NUMBER: 150:523475
TITLE: Polymorphs of rupatadine fumarate
INVENTOR(S): Darji, Dharmendra Arvindbhai; Patel, Mahesh Shankarbhai; Kumar, Rajiv; Dwivedi, Shriprakash Dhar
PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
SOURCE: Indian Pat. Appl., 30pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU01471	A	20080725	IN 2006-MU1471	20060915

PRIORITY APPLN. INFO.: IN 2006-MU1471 20060915

AB A crystalline form of rupatadine fumarate is characterized by x-ray powder diffraction.

IT 182349-12-8P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphs of rupatadine fumarate)

RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 158876-82-5
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(polymorphs of rupatadine fumarate)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L10 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:5893 ZCAPLUS
DOCUMENT NUMBER: 146:128584
TITLE: New disintegrant tablet formulation of rupatadine
INVENTOR(S): Liao, Juan; Chen, Yang
PATENT ASSIGNEE(S): Beijing D-Venturepharm.T. Corp., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1883480	A	20061227	CN 2005-10077340	20050622
PRIORITY APPLN. INFO.:			CN 2005-10077340	20050622

AB The invention provides a new disintegrant tablet formulation of rupatadine. The composition is composed of rupatadine, excipient, bulking agent, diluting agent, binding agent, disintegrant, lubricant, wetting agent, and sweetening agent. The formulation may be tablet, dispersing tablet, orally disintegrating tablet, and/or capsule. The preparation of tablet comprises, for example, (1) sieving rupatadine fumarate with 100 mesh sieve, magnesium stearate with 60 mesh sieve, other materials with 80 mesh sieve; (2) mixing main drug with lactose, then with other adjuvants; (3) prilling with 10% starch syrup, drying at 50 °C; (4) mixing with magnesium stearate, and pressing to obtain the product.
IT 158876-82-5, Rupatadine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new disintegrant tablet formulation of rupatadine)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L10 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:1030442 ZCAPLUS
DOCUMENT NUMBER: 145:397370
TITLE: Process for the preparation of a polymorphic crystalline form of rupatadine free base
INVENTOR(S): Parthasaradhi Reddy, Bandi; Rathnakar Reddy, Kura; Raji Reddy, Rapolu; Muralidhara Reddy, Dasari; Subash Chander Reddy, Kesireddy
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 15pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103688	A1	20061005	WO 2005-IN97	20050401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1863788	A1	20071212	EP 2005-742906	20050401
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2006CN01189	A	20070720	IN 2006-CN1189	20060406
US 20090197907	A1	20090806	US 2009-598846	20090324

PRIORITY APPLN. INFO.: WO 2005-IN97 W 20050401
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:397370
AB A novel crystalline form of rupatadine free base, a process for its preparation, and a pharmaceutical composition containing it are described. Rupatadine is suspended in n-hexane, n-heptane, cyclohexane, di-Et ether, or

diisopropyl ether, stirred for at least 1 h, the solid filtered and dried to give crystalline rupatadine form B.

IT 182349-12-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in a process for the preparation of a polymorphic crystalline form of rupatadine free base)

RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 158876-82-5P, Rupatadine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(process for the preparation of a polymorphic crystalline form of rupatadine free base)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

     FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
L1             STRUCTURE UPLOADED
L2           1 S SAM SSS L1

     FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
               S L1

     FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
L3           1 S L1 SSS SAM

     FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
L4           0 S L3 SSS SAM

     FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
L5           1 S SAM SSS L1
L6             STRUCTURE UPLOADED
L7           0 S SAM SSS L6
L8          31 S FULL SSS L6

     FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
L9         124 S L8

     FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

     FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011
L10          4 S L9 AND (CRYSTAL OR CRYSTALLINE)

=> s l9 and polymorph
         11005 POLYMORPH
         12989 POLYMORPHS
         19151 POLYMORPH
                 (POLYMORPH OR POLYMORPHS)
L11          1 L9 AND POLYMORPH

=> s l9 and polymorph?
```

```
        306775 POLYMORPH?
L12          5 L9 AND POLYMORPH?

=> s l12 not l10
L13          3 L12 NOT L10

=> s l9 (L) polymorph?
        306775 POLYMORPH?
L14          2 L9 (L) POLYMORPH?

=> s l9 (W) polymorph?
        306775 POLYMORPH?
L15          1 L9 (W) POLYMORPH?

=> s l14 not l13
L16          2 L14 NOT L13

=> s l14 and l13
L17          0 L14 AND L13

=> s l14 not l10
L18          0 L14 NOT L10

=> d ibib abs hitstr l13 1-3
THE ESTIMATED COST FOR THIS REQUEST IS 17.88 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13  ANSWER 1 OF 3  ZCAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:         2010:785907  ZCAPLUS
DOCUMENT NUMBER:          153:108912
TITLE:                    Oxepine modulators of h1 receptors and/or inhibitors
                          of mast cell degranulation
INVENTOR(S):              Gant, Thomas G.; Shahbaz, Manouchehr M.
PATENT ASSIGNEE(S):       Auspex Pharmaceuticals, Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 51pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 20100160272        A1    20100624    US 2009-641397          20091218
     WO 2010080577         A2    20100715    WO 2009-US68654         20091218
     WO 2010080577         A3    20101028
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
             ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
             MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
             PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
             ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                       US 2008-138568P     P  20081218
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):          MARPAT 153:108912
AB   The present invention relates to new oxepine modulators of H1 receptors
```

and/or inhibitors of mast cell degranulation, pharmaceutical compns. thereof, and methods of use thereof.

IT 158876-82-5, Rupatadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deuterium-enriched oxepine modulators of H1 receptors and/or inhibitors of mast cell degranulation)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L13 ANSWER 2 OF 3 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:596607 ZCAPLUS

DOCUMENT NUMBER: 152:548261

TITLE: Preparation of deuterated steroid modulators of glucocorticoid receptor

INVENTOR(S): Gant, Thomas G.; Shahbaz, Manouchehr

PATENT ASSIGNEE(S): Auspex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010054158	A2	20100514	WO 2009-US63501	20091106
WO 2010054158	A3	20100819		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20100120733	A1	20100513	US 2009-613628	20091106

PRIORITY APPLN. INFO.: US 2008-112268P P 20081107
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 152:548261
GI



I

AB The present invention relates to new steroid modulators I [R1 - R31 and R35 - R41 are independently selected from the group consisting of H or deuterium; R32 and R33 are independently selected from the group consisting of Me, CH2D, CHD2, CD3; R34 = OC(:O)CR41(CR35R36R37)(CR38R39R40); and at least one of R1 - R33 and R35 - R41 is deuterium or contains deuterium], or a pharmaceutically acceptable salt thereof, of glucocorticoid receptor activity, pharmaceutical compns. thereof, and methods of use thereof. The physiol. of I was studied using: an in vitro liver microsomal stability assay; an in vitro metabolism assay with human cytochrome P 450 enzymes; and, an assay with monoamine oxidase inhibition and oxidative turnover.

IT 158876-82-5, Rupatadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination chemotherapy antihistamine; preparation of deuterated steroid modulators of glucocorticoid receptor)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L13 ANSWER 3 OF 3 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:42786 ZCAPLUS
DOCUMENT NUMBER: 148:119180
TITLE: Genetic markers in tachykinin NK1 receptor gene TACR1 that correlate with asthma disorders
INVENTOR(S): Halapi, Eva; Hakonarson, Hakon
PATENT ASSIGNEE(S): Decode Genetics Ehf., USA
SOURCE: PCT Int. Appl., 133pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008006105	A2	20080110	WO 2007-US73066	20070709
WO 2008006105	A9	20080403		
WO 2008006105	A3	20080814		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-819198P P 20060707
OTHER SOURCE(S): MARPAT 148:119180

AB Polymorphisms in the exon 2 LD block of gene TACR1 encoding tachykinin receptor 1 are shown by association anal. to be a susceptibility gene for asthma. Methods of diagnosis of susceptibility to asthma, of decreased susceptibility to asthma and protection against asthma, are described, as are methods of treatment for asthma.

IT 158876-82-5, Rupatadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(genetic markers in tachykinin NK1 receptor gene TACR1 that correlate with asthma disorders)

RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
L1 STRUCTURE UPLOADED
L2 1 S SAM SSS L1

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
S L1

FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
L3 1 S L1 SSS SAM

FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
L4 0 S L3 SSS SAM

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
L5 1 S SAM SSS L1
L6 STRUCTURE UPLOADED
L7 0 S SAM SSS L6
L8 31 S FULL SSS L6

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
L9 124 S L8

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011
L10 4 S L9 AND (CRYSTAL OR CRYSTALLINE)
L11 1 S L9 AND POLYMORPH
L12 5 S L9 AND POLYMORPH?
L13 3 S L12 NOT L10
L14 2 S L9 (L) POLYMORPH?
L15 1 S L9 (W) POLYMORPH?
L16 2 S L14 NOT L13

```
L17           0 S L14 AND L13
L18           0 S L14 NOT L10

=> s l9/prep
FIELD CODES CANNOT BE CHANGED HERE
You may have tried to apply a field code to a term that already has a
field code.  You can only add a field code to a term that has no field
code appended to it.

=> s l8/prep
          124 L8
      5204403 PREP/RL
L19         21 L8/PREP
                (L8 (L) PREP/RL)

=> s l19 not l10
L20         19 L19 NOT L10

=> s l20 not l13
L21         19 L20 NOT L13

=> d ibib abs hitstr 17-19
THE ESTIMATED COST FOR THIS REQUEST IS 17.88 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L21  ANSWER 17 OF 19  ZCAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:        1996:635179  ZCAPLUS
DOCUMENT NUMBER:         125:275664
ORIGINAL REFERENCE NO.:  125:51553a,51556a
TITLE:                   8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-
                         piperidylidene]-6,11-dihydro-5H-
                         benzo[5,6]cyclohepta[1,2-b]pyridine fumarate and its
                         preparation and use as a PAF antagonist and
                         antihistaminic
INVENTOR(S):             Carceller, Elena; Recasens, Nuria; Almansa, Carmen;
                         Bartroli, Javier; Merlos, Manel; Giral, Marta
PATENT ASSIGNEE(S):      J. Uriach & Cia. S.A., Spain
SOURCE:                  Span., 11 pp.
                         CODEN: SPXXAD
DOCUMENT TYPE:           Patent
LANGUAGE:                Spanish
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     ES 2087818           A1    19960716    ES 1993-2460            19931124
     ES 2087818           B1    19970316
     NO 9404487           A     19950526    NO 1994-4487            19941123
PRIORITY APPLN. INFO.:                      ES 1993-2460        A   19931124
GI
```



I

AB The title salt I-fumarate is prepared for use as an antagonist of PAF (platelet activating factor) and an antihistaminic (no data). I-fumarate has improved hygroscopicity and light stability in comparison to I.3HCl or the free base I. For example, I was prepared from loratadine by a sequence of: hydrolytic removal of the N-ethoxycarbonyl group (84%), N-acylation with 5-methylnicotinic acid using DCC and HOBt (65%), and chlorination/reduction of the amide using POCl3 followed by NaBH4 (72%). Treatment of I with fumaric acid in EtOH gave 70% I-fumarate. When exposed to 98% humidity for 24 h, H2O contents were 5.7% for I, and 28.3% for I.3HCl, but only 0.29% for I-fumarate. Similarly, irradiation at 150 klx for 1 h reduced purities to 92.7% for I, to 74% for I.3HCl, but only to 99.2% for I.fumarate.

IT 158876-82-5P
RL: IMF (Industrial manufacture); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(comparison compound; preparation of benzocycloheptapyridine derivative fumarate
salt as PAF antagonist and antihistaminic with improved properties)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 156611-76-6P
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(comparison compound; preparation of benzocycloheptapyridine derivative fumarate
salt as PAF antagonist and antihistaminic with improved properties)

RN 156611-76-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

IT 182349-12-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzocycloheptapyridine derivative fumarate salt as PAF antagonist and antihistaminic with improved properties)

RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L21 ANSWER 18 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1994:680552 ZCAPLUS
DOCUMENT NUMBER: 121:280552
ORIGINAL REFERENCE NO.: 121:51219a,51222a
TITLE: Process for preparation of 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine and analogs as antihistaminics and PAF antagonists
INVENTOR(S): Carceller, Elena; Recasens, Nuria; Almansa, Carmen; Almansa, Javier; Merlos, Manuel; Giral, Marta; Garcia-Rafanell, Julian; Forn, Javier
PATENT ASSIGNEE(S): J. Uriach y Cia S.A., Spain
SOURCE: Span., 18 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2042421	A1	19931201	ES 1992-1054	19920522
ES 2042421	B1	19940801		
CA 2096318	A1	19931123	CA 1993-2096318	19930514
CA 2096318	C	19980623		
US 5407941	A	19950418	US 1993-61720	19930517
EP 577957	A1	19940112	EP 1993-108177	19930519

EP 577957	B1	19950712			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 06087856	A	19940329	JP 1993-117427		19930519
JP 2730612	B2	19980325			
AT 124939	T	19950715	AT 1993-108177		19930519
ES 2076817	T3	19951101	ES 1993-108177		19930519
KR 156518	B1	19981116	KR 1993-8812		19930521
US 5476856	A	19951219	US 1995-391702		19950221
PRIORITY APPLN. INFO.:			ES 1992-1054	A	19920522
			US 1993-61720	A1	19930517

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 121:280552

GI



I



II

AB Nine title compds. I [R = H, halo, C1-4 alkyl, C1-4 alkoxy] and a salt were prepared and tested. For example, the drug loratadine [II; R1 = CO2Et] was treated with Me3SiI in CHCl3 at 55-60° under Ar to give 77% II (R1 = H). N-alkylation of this by 3-methyl-5-(bromomethyl)pyridine [prepared in situ by NBS bromination of 3,5-lutidine] in CCl4 in the presence of DMAP gave 40% I (R = 5-Me) (III), the most active compound In a test for H1-antihistaminic activity, III was 20 times as potent as the known unsubstituted 4-pyridyl analog, and 25-70 times as potent as loratadine and 2 other carbonyl-containing analogs. In tests of I and the standard compds. for antagonism of platelet activating factor (PAF), only II showed potent activity, being at least 10-fold more active than the other compds.

IT 158876-82-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of [(pyridylmethyl)piperidylidene]benzocycloheptapyridine derivs. as antihistaminics and PAF antagonists)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 156522-82-6P 156522-86-0P 156522-87-1P
156522-88-2P 156522-89-3P 156522-94-0P
156522-95-1P 156611-76-6P 158876-81-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(pyridylmethyl)piperidylidene]benzocycloheptapyridine derivs. as antihistaminics and PAF antagonists)
RN 156522-82-6 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-(3-pyridinylmethyl)-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-86-0 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 11-[1-[(5-bromo-3-pyridinyl)methyl]-4-piperidinylidene]-8-chloro-6,11-dihydro- (CA INDEX NAME)



RN 156522-87-1 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-11-[1-[(6-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-dihydro- (CA INDEX NAME)



RN 156522-88-2 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-11-[1-[(2-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-dihydro- (CA INDEX NAME)



RN 156522-89-3 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-94-0 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(2-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-95-1 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(4-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156611-76-6 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 158876-81-4 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(6-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

L21 ANSWER 19 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1994:524597 ZCAPLUS
DOCUMENT NUMBER: 121:124597
ORIGINAL REFERENCE NO.: 121:22229a,22232a
TITLE: [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine
AUTHOR(S): Carceller, Elena; Merlos, Manuel; Giral, Marta; Balsa, Dolors; Almansa, Carmen; Bartroli, Javier; Garcia-Rafanell, Julian; Forn, Javier
CORPORATE SOURCE: Research Center, J. Uriach Cia.S.A., Barcelona, 08026,

Spain
SOURCE: Journal of Medicinal Chemistry (1994), 37(17), 2697-703
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:124597

AB A series of [(3-pyridylalkyl)piperidylidene]- and (nicotinoylpiperidylidene)benzocycloheptapyridine derivs. were prepared and evaluated for PAF antagonist and H1 antihistamine activity. PAF antagonist activity was investigated by the in vitro PAF-induced platelet aggregation assay (PPA) and the in vivo PAF-induced hypotension test in rats (PH) and mortality test in mice (PM). For the evaluation of H1 antihistamine activity, the in vitro histamine-induced contraction of the guinea-pig ileum assay (HC) and the in vivo histamine-induced hypotension test (HH) in normotensive rats were used. The potential antiallergic activity of the compds. was evaluated using the active anaphylactic shock test in mice. These compds. are structurally related to loratadine (1) and were generated by replacement of the ethoxycarbonyl group of 1 with substituted 3-pyridylmethyl and nicotinoyl moieties. Both anti-PAF and H1 antihistamine activities have shown a high dependence on the exact nature and position of the substituent in the pyridine ring. The optimum structure, incorporating a (5-methyl-3-pyridyl)methyl radical, displayed an unique dual activity inhibiting both PAF-induced effects (PPA, IC50 = 3.7 μM; PH, ID50 = 0.44 mg/kg i.v.; PM, ID50 = 1.9 mg/kg po) and histamine-induced effects (HC, IC50 = 3.9 nM; HH, ID50 = 1.4 mg/kg i.v.). Furthermore, this compound was highly active in the passive cutaneous anaphylactic shock in rats (ID50 = 1.2 mg/kg po) and strongly protected mice and rats from mortality induced by endotoxin (ID50 = 1.2 and 0.5 mg/kg i.v., resp.). It showed itself to be devoid of CNS depressant effects, neither modifying spontaneous motor activity nor prolonging barbiturate-sleeping time in mice at a dose of 100 mg/kg po, and is now under development.

IT 156522-82-6P 156522-83-7P 156522-86-0P
156522-87-1P 156522-88-2P 156522-89-3P
156522-90-6P 156522-91-7P 156522-92-8P
156522-93-9P 156522-94-0P 156522-95-1P
156611-76-6P, UR 12592
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antihistaminic and PAF-antagonistic activity of, structure in relation to)

RN 156522-82-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-(3-pyridinylmethyl)-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-83-7 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(1-oxido-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-86-0 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 11-[1-[(5-bromo-3-pyridinyl)methyl]-4-piperidinylidene]-8-chloro-6,11-dihydro- (CA INDEX NAME)



RN 156522-87-1 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-11-[1-[(6-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-dihydro- (CA INDEX NAME)



RN 156522-88-2 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-11-[1-[(2-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-dihydro- (CA INDEX NAME)



RN 156522-89-3 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-90-6 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(2-methoxy-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-91-7 ZCAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 156522-92-8 ZCAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 156522-93-9 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(6-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 156522-94-0 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(2-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156522-95-1 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(4-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



RN 156611-76-6 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

=> d ibib abs hitstr 6-16
THE ESTIMATED COST FOR THIS REQUEST IS 65.56 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L21 ANSWER 6 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:848861 ZCAPLUS
DOCUMENT NUMBER: 150:398361
TITLE: Process for preparation of highly pure Rupatadine and intermediates
INVENTOR(S): Patel, Mahesh Shankarbhai; Kumar, Rajiv; Dwivedi, Shriprakash Dhar
PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
SOURCE: Indian Pat. Appl., 28pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00864	A	20080704	IN 2006-MU864	20060605
PRIORITY APPLN. INFO.:			IN 2006-MU864	20060605

OTHER SOURCE(S): CASREACT 150:398361; MARPAT 150:398361
AB This invention provides a process for the preparation of ACH2OSO2R [wherein A = 5-methyl-3-pyridyl; R = Me, Et, Pr, iso-Pr, Bu, iso-Bu, benzyl, tolyl, etc.] as intermediates for synthesizing highly pure Rupatadine. For example, Me 5-methylnicotinate was reduced with sodium borohydride to obtain 5-methyl-3-pyridylmethanol, followed by reaction with 4-methylbenzenesulfonyl chloride to give 5-methyl-3-pyridinemethanol tosylate. The previous obtained sulfonate was reacted with Desloratadine in acetone at 30-35 °C to give Rupatadine.
IT 158876-82-5P, Rupatadine
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of highly pure Rupatadine and intermediates)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 182349-12-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of highly pure Rupatadine and intermediates)

RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



L21 ANSWER 7 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:1468011 ZCAPLUS
DOCUMENT NUMBER: 148:262449
TITLE: Expedient synthesis of rupatadine
AUTHOR(S): Agarwal, Rajendra; Bhirud, Shekhar Bhaskar; Bijukumar, Gopinathenpillai; Khude, Gopal Dnyandev
CORPORATE SOURCE: Research and Development Centre, Chemical Process Research and Development, Macleods Pharmaceuticals Ltd., Mumbai, India
SOURCE: Synthetic Communications (2008), 38(1), 122-127
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:262449
AB Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF), was synthesized in 91% overall yield.
IT 158876-82-5P, Rupatadine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of rupatadine starting from methylnicotinic acid)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 182349-12-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of rupatadine starting from methylnicotinic acid)
RN 182349-12-8 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:1460686 ZCAPLUS
DOCUMENT NUMBER: 149:513665
TITLE: Synthesis of 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (rupatadine)
AUTHOR(S): Zhang, Wanjin; Luo, Yan; Zhang, Yanmei
CORPORATE SOURCE: Dept. of Medicinal Chemistry, Guangdong Pharmaceutical College, Guangzhou, Guangdong Province, 510224, Peop. Rep. China
SOURCE: Zhongguo Yiyao Gongye Zazhi (2006), 37(7), 433-435
CODEN: ZYGZEA; ISSN: 1001-8255
PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 149:513665
AB Rupatadine was synthesized from 2-cyano-3-methylpyridine by a synthetic sequence involving a Ritter reaction, alkylation, cyanidation, hydrolysis and cyclization to give 8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one, which was subjected to Grignard reaction and then dehydration with an overall yield of 18.7%.

IT 158876-82-5P, Rupatadine
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of rupatadine via synthetic sequence involving Ritter reaction, alkylation, cyanation, hydrolysis, cyclization, formation of chlorodihydrobenzo[5,6]cyclohepta[1,2-b]pyridinone, Grignard reaction and dehydration)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L21 ANSWER 9 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:655783 ZCAPLUS
DOCUMENT NUMBER: 148:426751
TITLE: Process for the synthesis of rupatadine
INVENTOR(S): Rajendra, Agarwal; Gopinathan, Pillai Bijukumar; Dnyandev, Khude Gopal; Bhaskar, Bhirud Shekhar
PATENT ASSIGNEE(S): MacLeods Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 14pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU02102	A	20070608	IN 2006-MU2102	20061222
PRIORITY APPLN. INFO.:			IN 2006-MU2102	20061222

OTHER SOURCE(S): CASREACT 148:426751
AB An improved and industrially feasible process for the preparation of 8-chloro-6,1-dihydro-11-[1-[(methyl-3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2b]pyridine (rupatadine). Rupatadine was prepared by esterification of 5-methylnicotinic acid; the resulting 5-methylnicotinate underwent reduction to give 5-methylpyridine-3-methanol, which underwent chlorination to give the corresponding chloromethylpyridine, which underwent condensation with desloratadine to give rupatadine, which was reacted with fumaric acid to give rupatadine fumarate.
IT 158876-82-5P, Rupatadine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the synthesis of rupatadine)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 182349-12-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(process for the synthesis of rupatadine)

RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L21 ANSWER 10 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:1236016 ZCAPLUS
DOCUMENT NUMBER: 146:45400
TITLE: Method for preparation of Rupatadine and its salt
INVENTOR(S): Qu, Feng; Wang, Yusheng
PATENT ASSIGNEE(S): Beijing Dezhong-Venture Pharmaceutical Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 6pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1865259	A	20061122	CN 2005-10070952	20050519
CN 1865259	B	20100929		
PRIORITY APPLN. INFO.:			CN 2005-10070952	20050519

OTHER SOURCE(S): CASREACT 146:45400
GI



I

AB In this invention, Rupatadine is prepared by the reduction of I amide carbonyl group with Red-Al in THF, toluene, or DMF. Rupatadine can be obtained by reducing the amido bonds in the mols. of the compound or its salt in formula II in the presence of Red-Al.

IT 158876-82-5P, Rupatadine
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of Rupatadine via the reduction of amide carbonyl group with Red-Al)

RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L21 ANSWER 11 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:1147779 ZCAPLUS
DOCUMENT NUMBER: 145:471404
TITLE: Process for the preparation of rupatadine by PTC-catalyzed N-alkylation of desloratadine
INVENTOR(S): Khamar, Bakulesh Mafatlal; Modi, Indravadan Ambalal; Chandrakant, Shukla Manish; Kashyapbhai, Parikh Krunal; Prabhakar, Dange Suryabhan; Ravi, Ponniah; Jagdish, Desai Sanjay; Raman, J. Venkat
PATENT ASSIGNEE(S): Mafatlal, Khamar, Bakulesh, India; Ambalal, Modi, Indravadan; Chandrakant, Shukla, Manish; Kashyapbhai, Parikh, Krunal; Prabhakar, Dange, Suryabhan; Jagdish, Desai, Sanjay; Raman, J., Venkat
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114676	A2	20061102	WO 2006-IB964	20060422
WO 2006114676	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2005MU00516	A	20090626	IN 2005-MU516	20050427
ES 2311426	A1	20090201	ES 2007-50036	20060422
ES 2311426	B1	20091222		

PRIORITY APPLN. INFO.: IN 2005-MU516 A 20050427
OTHER SOURCE(S): CASREACT 145:471404
AB A process for the preparation of rupatadine, a potent orally active dual antagonist of platelet-activated factor and histamine, which comprises N-alkylating desloratadine with 3-(bromomethyl)-5-methylpyridine (I) or analogs in biphasic solvent systems, is disclosed. For instance, a mixture of desloratadine, dichloromethane, tetrabutylammonium bromide and NaOH aqueous solution is cooled to 0-5°C. After a mixture of I·HCl in dichloromethane was added, the whole was stirred at 0-5°C for 1 h and then at rt for 12 h to give rupatadine in 67.66% yield. A solution of this product in acetone was stirred with a solution of fumaric acid in methanol to afford rupatadine fumarate.
IT 158876-82-5P, Rupatadine
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of rupatadine via PTC-catalyzed N-alkylation of desloratadine in biphasic solvent systems)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 913746-24-4P 913746-25-5P 913746-26-6P
913746-27-7P 913746-28-8P 913746-29-9P
913746-30-2P 913746-31-3P 913746-32-4P
913746-33-5P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of rupatadine via PTC-catalyzed N-alkylation of desloratadine in biphasic solvent systems)
RN 913746-24-4 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 913746-25-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrobromide (1:?) (CA INDEX NAME)



●x HBr

RN 913746-26-6 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 913746-27-7 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 913746-28-8 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 913746-29-9 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 913746-30-2 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913746-31-3 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 913746-32-4 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 913746-33-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 12 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:620660 ZCAPLUS
DOCUMENT NUMBER: 146:142463
TITLE: Improved synthesis of 5-methylpyridine-3-carboxylic

acid, the intermediate of rupatadine
AUTHOR(S): Wang, Zhen-yu; Zhu, Xiong; Wang, Er-hua
CORPORATE SOURCE: Medicinal and Chemical Institute, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China
SOURCE: Yaoxue Jinzhan (2005), 29(1), 31-33
CODEN: YJAIBE; ISSN: 1001-5094
PUBLISHER: Yaoxue Jinzhan Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 146:142463

AB Objective: To improve the synthesis of 5-methylpyridine-3-carboxylic acid. Methods: 5-methylpyridine-3-carboxylic acid, the intermediate of Rupatadine, was synthesized from 3,5-lutidine by the reaction of oxidation with KMnO4. The reaction conditions were optimized with the orthogonal matrix. Results: The suitable conditions were obtained, and the yield was 51%.

IT 158876-82-5P, Rupatadine
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 5-methylpyridine-3-carboxylic acid as intermediate of rupatadine)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L21 ANSWER 13 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:515027 ZCAPLUS
DOCUMENT NUMBER: 144:369863
TITLE: Synthesis of Rupatadine
AUTHOR(S): Xin, Shiu-bo; Wu, Fan-hong
CORPORATE SOURCE: College of Chemistry and Pharmaceutics, East China University of Science and Technology, Shanghai, 200237, Peop. Rep. China
SOURCE: Zhongguo Xinyao Zazhi (2005), 14(4), 451-452
CODEN: ZXZHA6; ISSN: 1003-3734
PUBLISHER: Zhongguo Xinyao Zazhishe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB Rupatadine was prepared from Loratadine via hydrolysis and alkylation to provide the product with overall yield 32.4%.

IT 158876-82-5P, Rupatadine
RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of Rupatadine)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L21 ANSWER 14 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2003:652131 ZCAPLUS
DOCUMENT NUMBER: 139:214237
TITLE: Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
INVENTOR(S): Scaramuzzino, Giovanni
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 313 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213

GI



II

AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ-tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thoinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 = COCH2CH(M2)CH2N+Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, α-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT 586349-06-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)

RN 586349-06-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, nitrate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2

CRN 7697-37-2
CMF H N O3



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 15 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1999:579665 ZCAPLUS
DOCUMENT NUMBER: 131:184874
TITLE: Preparation of 8-chloro-6,11-dihydro-11[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
INVENTOR(S): Carceller, Elena; Jimenez, Perez J.; Salas, Jordi
PATENT ASSIGNEE(S): J. Uriach & Cia. S. A., Spain
SOURCE: Span., 10 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2120899	A1	19981101	ES 1996-2107	19961007
ES 2120899	B1	19990616		
PRIORITY APPLN. INFO.:			ES 1996-2107	19961007

GI



I

AB UR-12592 (I) was prepared by coupling 8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one with N-[(5-methyl-3-pyridinyl)methyl]-4-chloropiperidine and dehydrating with H2SO4.

IT 158876-82-5P, 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 8-chloro-6,11-dihydro-11[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (UR-12592))

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L21 ANSWER 16 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1997:30150 ZCAPLUS

DOCUMENT NUMBER: 126:69591

ORIGINAL REFERENCE NO.: 126:13317a,13320a

TITLE: Rupatadine fumarate. UR-12592 fumarate. Antiallergic. Histamine and PAF antagonist

AUTHOR(S): Garcia-Rafanell, J.
CORPORATE SOURCE: J. Uriach and Cia., Barcelona, 08026, Spain
SOURCE: Drugs of the Future (1996), 21(10), 1032-1036
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review, with 21 refs., describing the synthesis, pharmacol. actions, pharmacokinetics, toxicity, and clin. uses of the title drug.

IT 158876-82-5P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and pharmacol. of)

RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
L1 STRUCTURE UPLOADED
L2 1 S SAM SSS L1

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
S L1

FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
L3 1 S L1 SSS SAM

FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
L4 0 S L3 SSS SAM

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011

```
L5             1 S SAM SSS L1
L6               STRUCTURE UPLOADED
L7             0 S SAM SSS L6
L8            31 S FULL SSS L6

     FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
L9           124 S L8

     FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

     FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011
L10            4 S L9 AND (CRYSTAL OR CRYSTALLINE)
L11            1 S L9 AND POLYMORPH
L12            5 S L9 AND POLYMORPH?
L13            3 S L12 NOT L10
L14            2 S L9 (L) POLYMORPH?
L15            1 S L9 (W) POLYMORPH?
L16            2 S L14 NOT L13
L17            0 S L14 AND L13
L18            0 S L14 NOT L10
L19           21 S L8/PREP
L20           19 S L19 NOT L10
L21           19 S L20 NOT L13

=> exit
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               149.04     355.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -18.27     -18.27

STN INTERNATIONAL LOGOFF AT 09:27:45 ON 13 APR 2011
```